Phase II study of skin toxicity dosing of Iressa (gefitinib) as monotherapy in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2013
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 20 Nov 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Jun 2012 Planned End Date changed from 1 Mar 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
- 09 Jun 2011 Actual initiation date changed from Oct 2005 to Mar 2005 as reported by ClinicalTrials.gov.